News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Apr 20, 2022
Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious DiseaseApr 19, 2022
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022Mar 29, 2022
Clover Reports Full Year 2021 Financial ResultsMar 17, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a BoosterFeb 24, 2022
Clover Selected for Inclusion on the Hang Seng Composite IndexFeb 14, 2022
Clover Provides Corporate Update and 2022 PrioritiesFeb 01, 2022
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and DevelopmentJan 21, 2022
Clover's Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The LancetJan 05, 2022
Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRAJan 05, 2022
Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai
